September 6, 2023 05:48 AM EDTUpdated 06:04 AM

AstraZeneca’s Ultomiris label expansion stalls after FDA rejects sBLA, asks for REMS changes

Reynald Castañeda

Deputy Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Is there still hope for Summit's cancer drug buried in the data?

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

At a crossroads, biotechs are passing on reverse mergers in 2025

GSK taps Sanofi vet to lead vaccine R&D; Bristol Myers names head of corporate affairs

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...